← Back to Search

Virus Therapy

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

Phase 1
Waitlist Available
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions

Summary

This trial will test a new malaria vaccine on 28 healthy volunteers to see if it's safe and effective. They'll get doses of the vaccine and a malaria drug & be tested for infection 10 wks later.

Eligible Conditions
  • Malaria

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

3Treatment groups
Active Control
Group I: Group 1: PfSPZ 51200 sporozoites/PlaceboActive Control3 Interventions
Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
Group II: Group 2: PfSPZ 102400 sporozoites/PlaceboActive Control3 Interventions
CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
Group III: Group 3: PfSPZ 102400 sporozoitesActive Control2 Interventions
CQ/PfSPZ Challenge 102400 sporozoites N=9

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,336 Previous Clinical Trials
5,392,736 Total Patients Enrolled
155 Trials studying Malaria
439,113 Patients Enrolled for Malaria
~3 spots leftby Jan 2026